ONWARD MEDICAL BV EO -12 Net Assets
ONWARD MEDICAL BV EO -12 net assets. Based on the latest financial reports, ONWARD MEDICAL BV EO -12 (63E) has net assets worth €55.32 Million EUR (≈ $64.67 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€84.55 Million ≈ $98.85 Million USD) and total liabilities (€29.24 Million ≈ $34.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is ONWARD MEDICAL BV EO -12 growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €55.32 Million |
| % of Total Assets | 65.42% |
| Annual Growth Rate | -9.56% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 90.12 |
Net Assets of ONWARD MEDICAL BV EO -12 (2021–2025)
Net assets of ONWARD MEDICAL BV EO -12 from 2021 to 2025. This chart illustrates how ONWARD MEDICAL BV EO -12's net assets have evolved over time, based on quarterly financial data. See 63E equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for ONWARD MEDICAL BV EO -12 (2021–2025)
The table below shows the annual net assets of ONWARD MEDICAL BV EO -12 from 2021 to 2025. For live market cap and overall valuation, see market cap of ONWARD MEDICAL BV EO -12.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €55.32 Million ≈ $64.67 Million |
+15.11% |
| 2024-12-31 | €48.05 Million ≈ $56.18 Million |
+167.99% |
| 2023-12-31 | €17.93 Million ≈ $20.96 Million |
-65.93% |
| 2022-12-31 | €52.63 Million ≈ $61.53 Million |
-36.35% |
| 2021-12-31 | €82.68 Million ≈ $96.67 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ONWARD MEDICAL BV EO -12's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14658400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
ONWARD MEDICAL BV EO -12 Net Assets Breakdown (December 2025)
ONWARD MEDICAL BV EO -12 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €277.87 Million | 502.34% |
| Total Equity | €55.32 Million | 100.00% |
ONWARD MEDICAL BV EO -12 Competitors by Market Cap
The table below lists competitors of ONWARD MEDICAL BV EO -12 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rajesh Exports Limited
NSE:RAJESHEXPO
|
$157.87 Million |
|
MKH Oil Palm (East Kalimantan) Berhad
KLSE:5319
|
$157.89 Million |
|
La Finca Global Assets SOCIMI S.A.
MC:YLFG
|
$157.98 Million |
|
NoHo Partners Oyj
HE:NOHO
|
$158.04 Million |
|
Vuzix Corp Cmn Stk
NASDAQ:VUZI
|
$157.85 Million |
|
Mountain & I Acquisition Co Corp
NASDAQ:MCAA
|
$157.81 Million |
|
Adagene Inc
NASDAQ:ADAG
|
$157.79 Million |
|
Ram Essential Services Property Fund
AU:REP
|
$157.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONWARD MEDICAL BV EO -12's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 48,054,000 to 55,316,000, a change of 7,262,000 (15.1%).
- Net loss of 41,787,000 reduced equity.
- New share issuances of 51,187,000 increased equity.
- Other factors decreased equity by 2,138,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-41.79 Million | -75.54% |
| Share Issuances | €51.19 Million | +92.54% |
| Other Changes | €-2.14 Million | -3.87% |
| Total Change | €- | 15.11% |
Book Value vs Market Value Analysis
This analysis compares ONWARD MEDICAL BV EO -12's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.97x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.71x to 1.97x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.74 | €1.94 | x |
| 2022-12-31 | €1.74 | €1.94 | x |
| 2023-12-31 | €0.59 | €1.94 | x |
| 2024-12-31 | €1.08 | €1.94 | x |
| 2025-12-31 | €0.99 | €1.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ONWARD MEDICAL BV EO -12 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -75.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1105.48%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.53x
- Recent ROE (-75.54%) is above the historical average (-91.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -41.50% | 0.00% | 0.00x | 1.27x | €-42.58 Million |
| 2022 | -62.27% | -31511.54% | 0.00x | 1.46x | €-38.04 Million |
| 2023 | -201.78% | -53207.35% | 0.00x | 2.43x | €-37.97 Million |
| 2024 | -74.34% | -15600.44% | 0.00x | 1.58x | €-40.53 Million |
| 2025 | -75.54% | -1105.48% | 0.04x | 1.53x | €-47.32 Million |
Industry Comparison
This section compares ONWARD MEDICAL BV EO -12's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $82,275,373
- Average return on equity (ROE) among peers: -15.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONWARD MEDICAL BV EO -12 (63E) | €55.32 Million | -41.50% | 0.53x | $157.86 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-294.00K | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $141.29 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-223.84 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $125.74 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $218.97 Million | -16.25% | 0.03x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $699.56 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
About ONWARD MEDICAL BV EO -12
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more